7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Oxidant Sensing by TRPM2 Inhibits Neutrophil Migration and Mitigates Inflammation

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          SUMMARY

          Blood neutrophils perform an essential host-defense function by directly migrating to bacterial invasion sites to kill bacteria. The mechanisms mediating the transition from the migratory to bactericidal phenotype remain elusive. Here, we demonstrate that TRPM2, a trp superfamily member, senses neutrophil-generated reactive oxygen species and restrains neutrophil migration. The inhibitory function of oxidant sensing by TRPM2 requires the oxidation of Cys549, which then induces TRMP2 binding to formyl peptide receptor 1 (FPR1) and subsequent FPR1 internalization and signaling inhibition. The oxidant sensing-induced termination of neutrophil migration at the site of infection permits a smooth transition to the subsequent microbial killing phase.

          In Brief

          The molecular switches that turn a chemotactic neutrophil into a microbial killing machine are still unclear. Wang et al. show that, upon reaching the site of infection, increased ROS production by neutrophils—via a respiratory burst sensed by neutrophil TRPM2—stops cell migration and promotes a switch to microbial killing.

          Related collections

          Author and article information

          Journal
          101120028
          22411
          Dev Cell
          Dev. Cell
          Developmental cell
          1534-5807
          1878-1551
          7 April 2017
          25 August 2016
          12 September 2016
          02 June 2017
          : 38
          : 5
          : 453-462
          Affiliations
          [1 ]Department of Pharmacology, University of Illinois, Chicago, IL 60612, USA
          [2 ]Chemotaxis Signal Section, Laboratory of Immunogenetics, NIAID, NIH, Bethesda, MD 20892, USA
          [3 ]Proteomic Core Facility, NHLBI, NIH, Bethesda, MD 20824, USA
          [4 ]Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
          [5 ]Department of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
          Author notes
          [* ]Correspondence: jingsong.xu@ 123456hotmail.com
          [6]

          Co-first author

          [7]

          Present address: Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical College, Jiangsu 221002, China

          [8]

          Present address: Department of Cardiology, Howard Hughes Medical Institute, Boston Children’s Hospital, Boston, MA 02115, USA

          [9]

          Present address: Becton Dickinson, Vernon Hills, IL 60061, USA

          [10]

          Present address: Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA

          [11]

          Lead Contact

          Article
          PMC5455786 PMC5455786 5455786 nihpa859703
          10.1016/j.devcel.2016.07.014
          5455786
          27569419
          5d32a36f-56ea-45a2-b760-405856142a5d
          History
          Categories
          Article

          Comments

          Comment on this article